Skip to search formSkip to main contentSkip to account menu

octreotate, Tyr(3)-

Known as: (Tyr(3))octreotate, 3-Tyr-octreotate, octreotate, tyrosyl(3)- 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cyclic Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA…
Background Lutetium-177-DOTA-octreotate ( 177 Lu-DOTATATE) significantly increases survival and response rates in patients with… 
Highly Cited
2018
Highly Cited
2018
Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy
Purpose: Radionuclide therapy directed against tumors that express somatostatin receptors (SSTRs) has proven effective for the… 
Review
2014
Review
2014
Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors
PurposeTo demonstrate the safety of outpatient 7.8 GBq 177Lu-DOTA-tyr3-octreotate radiopeptide therapy of neuroendocrine tumors… 
2014
2014
Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice.
Highly Cited
2013
Highly Cited
2013
Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment
The organs at risk in radionuclide therapy with 177Lu-octreotate are the bone marrow and the kidneys. The primary aim of this… 
Highly Cited
2012
Highly Cited
2012
Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
BackgroundExternal beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression… 
2012
2012
Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131.
Our objectives were to automate radiolabeling of therapeutic activities for safe, reliable, cost-effective, practical routine… 
2012
2012
Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.
A patient with advanced pancreatic neuroendocrine carcinoma and liver metastases underwent explorative laparotomy, which… 
Highly Cited
2011
Highly Cited
2011
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs… 
Highly Cited
2010
Highly Cited
2010
One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission…
The synthesis, radiolabeling, and initial evaluation of new silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)